Ionis Pharmaceuticals Bolsa (NASDAQ: IONS)

Últimas noticias sobre Ionis Pharmaceuticals (NASDAQ:IONS) Bolsa

Ionis Pharmaceuticals

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals Inc

IONIS PHARMACEUTICALS ORD

Rocket Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKT#NASDAQ">RCKT</a>) reported quarterly losses of $(0.71) per share which beat the analyst consensus estimate of $(0.75) by 5.33 percent.

Earnings

Earnings Beats

News

RCKT

Rocket Pharmaceuticals Q3 2024 GAAP EPS $(0.71) Beats $(0.75) Estimate

CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) affirms FY2024 sales outlook from $225.00 million-235.00 million to $225.00 million-235.00 million.

Guidance

CYRX

CryoPort Affirms FY2024 Sales Guidance to $225.00M-235.00M  VS Est.229.73M

NV5 Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVEE#NASDAQ">NVEE</a>) reported quarterly earnings of $0.44 per share which beat the analyst consensus estimate of $0.41 by 7.32 percent. This is a 22.22 percent increase over earnings of $0.36 per share from the same period last year. The company reported quarterly sales of $250.885 million which missed the analyst consensus estimate of $252.108 million by 0.49 percent. This is a 4.85 percent increase over sales of $239.287 million the same period last year.

Earnings Misses

NVEE

NV5 Global Q3 2024 Adj. EPS $0.44 Beats $0.41 Estimate, Sales $250.885M Miss $252.108M Estimate

FRLA

Fortune Rise Acquisition Extends To Complete Business Combination From Nov. 5 To Dec. 5

WIIM

PRPH

ProPhase Labs shares are trading lower after the company announced its intention to sell shares through a public offering.

Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.02 by 200 percent. The company reported quarterly sales of $213.300 million which beat the analyst consensus estimate of $210.729 million by 1.22 percent. This is a 11.15 percent increase over sales of $191.900 million the same period last year.

MYGN

Myriad Genetics Q3 2024 Adj. EPS $0.06 Beats $0.02 Estimate, Sales $213.300M Beat $210.729M Estimate

Buybacks

DVAX

Dynavax Launches $200M Share Buyback Program With Board Approval; Repurchases Expected To Be Completed Within One Year

ON24 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONTF#NYSE">ONTF</a>) raises FY2024 Adj EPS guidance from $0.05-0.08 to $0.08-0.10 vs $0.07 analyst estimate. Raises FY2024 sales outlook from $145.00 million-147.80 million to $146.80 million-147.80 million vs $146.33 million estimate.

ONTF

ON24 Raises FY2024 Adj EPS Guidance from $0.05-0.08 to $0.08-0.10 vs $0.07 Est; Raises FY2024 Sales Guidance from $145.00M-147.80M to $146.80M-147.80M vs $146.33M Est

Bloom Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) affirms FY2024 sales outlook from $1.40 billion-1.60 billion to $1.40 billion-1.60 billion.

Bloom Energy Affirms FY2024 Sales Guidance to $1.40B-1.60B  VS Est.1.47B

Phunware (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHUN#NASDAQ">PHUN</a>) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.26) by 3.85 percent. This is a 90 percent increase over losses of $(2.50) per share from the same period last year. The company reported quarterly sales of $665.00 thousand which missed the analyst consensus estimate of $1.31 million by 49.24 percent. This is a 46.88 percent decrease over sales of $1.25 million the same period last year.

PHUN

Phunware Q3 EPS $(0.25) Beats $(0.26) Estimate, Sales $665.00K Miss $1.31M Estimate

Apartment Inv &amp; Mgmt (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIV#NYSE">AIV</a>) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.11) by 45.45 percent. This is a 700 percent decrease over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $53.16 million which beat the analyst consensus estimate of $52.60 million by 1.06 percent. This is a 11.44 percent increase over sales of $47.70 million the same period last year.

Apartment Inv & Mgmt Q3 EPS $(0.16) Misses $(0.11) Estimate, Sales $53.16M Beat $52.60M Estimate

New facility will enable testing of liquid hydrogen (LH2), liquid oxygen (LOX) and liquid methane (LCH4)

Graham To Construct Cryogenic Propellant Testing Facility

ON24 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONTF#NYSE">ONTF</a>) is looking for Q4 Adj EPS of $0.01-0.02 vs $0.01 analyst estimate. sees sales of $35.400 million-36.400 million vs $35.87 million estimate.

ON24 Sees Q4 Adj EPS $0.01-0.02 vs $0.01 Est; Sees Sales $35.400M-36.400M vs $35.87M Est

MRVI

Maravai LifeSciences To Acquire Officinae Bio's DNA And RNA Business, Enhancing Nucleic Acid Research Capabilities; Acquisition To Boost Maravai's mRNA Manufacturing Through TriLink BioTechnologies

Lionsgate Studios (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LION#NASDAQ">LION</a>) reported quarterly losses of $(0.39) per share which missed the analyst consensus estimate of $(0.06) by 550 percent. This is a 750 percent decrease over earnings of $0.06 per share from the same period last year. The company reported quarterly sales of $823.70 million which beat the analyst consensus estimate of $748.00 million by 10.12 percent.

LION

Lionsgate Studios Q2 2025 GAAP EPS $(0.39) Misses $(0.06) Estimate, Sales $823.70M Beat $748.00M Estimate

Lantronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRX#NASDAQ">LTRX</a>) is looking for Q2 Adj EPS of $0.01-0.05 vs $0.10 analyst estimate. sees sales of $29.000 million-33.000 million vs $38.60 million estimate.

LTRX

Lantronix Sees Q2 Adj EPS $0.01-0.05 vs $0.10 Est; Sees Sales $29.000M-33.000M vs $38.60M Est

FIGS

FIGS shares are trading lower after the company reported worse-than-expected Q3 revenue results and cut its FY24 revenue guidance.

BlackLine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BL#NASDAQ">BL</a>) is looking for Q4 Adj EPS of $0.47-0.52 vs $0.51 analyst estimate. seessales of $167.000 million-169.000 million vs $168.08 million estimate.

BlackLine Sees Q4 Adj EPS $0.47-0.52 vs $0.51 Est; Sees Sales $167.000M-169.000M vs $168.08M Est

Adeia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADEA#NASDAQ">ADEA</a>) lowers FY2024 sales outlook from $380.00 million-420.00 million to $370.00 million-400.00 million.

ADEA

Adeia Lowers FY2024 Sales Guidance from $380.00M-420.00M to $370.00M-400.00M

Longboard Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBPH#NASDAQ">LBPH</a>) reported quarterly losses of $(0.63) per share which missed the analyst consensus estimate of $(0.57) by 10.53 percent.

LBPH

Longboard Pharmaceuticals Q3 2024 GAAP EPS $(0.63) Misses $(0.57) Estimate

Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS – CVS Health (CVS) up 12% Vertex (VERX) up 6% I...

Morning Movers: CVS Health surges and ODP sinks following Q3 results

Ionis Pharmaceuticals, Inc. 2024 Q3 - Results - Earnings Call Presentation

Ionis reaches agreement on phase 3 trial design for Angelman candidate

Ionis Pharmaceuticals, Inc. (IONS) Q3 2024 Earnings Call Transcript

Ionis Pharmaceuticals (IONS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Stringe...

Buy Rating for Ionis Pharmaceuticals: Strong Financials and Promising Clinical Developments

Yaron Werber, an analyst from TD Cowen, maintained the Buy rating on Ionis Pharmaceuticals (IONS – Research Report). The associated price target re...

Ionis Pharmaceuticals: Strategic Developments and Robust Pipeline Justify Buy Rating

Ionis Pharmaceuticals Inc. ( ($IONS) ) has released its Q3 earnings. Here is a breakdown of the information Ionis Pharmaceuticals Inc. presented to...

Ionis Pharmaceuticals Reports Q3 2024 Financial Results

In a report released today, Gena Wang from Barclays maintained a Hold rating on Ionis Pharmaceuticals (IONS – Research Report), with a price target...

Ionis Pharmaceuticals (IONS) Gets a Hold from Barclays

Wells Fargo lowered the firm's price target on Ionis Pharmaceuticals (IONS) to $77 from $82 and keeps an Overweight rating on the shares. The firm ...

Ionis Pharmaceuticals price target lowered to $77 from $82 at Wells Fargo

Stifel Nicolaus analyst Paul Matteis maintained a Hold rating on Ionis Pharmaceuticals (IONS – Research Report) today and set a price target of $45...

Stifel Nicolaus Sticks to Its Hold Rating for Ionis Pharmaceuticals (IONS)

ATHM

AUDC

CELH

ENOV

EXAS

GMED

HNDAF

IONS

IRBT

VERX

Offerings

Press Releases

Ionis announces pricing of $500.3 million public offering

Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease

New positive donidalorsen data to be presented at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA

WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis

Comments

Ionis Pharmaceuticals

Noticias

Últimas noticias sobre Ionis Pharmaceuticals (NASDAQ:IONS) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL